trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['solid tumor', 'pantumor', 't-dxd']
#asco23 efficacy and safety of t-dxd in pts with her2-expressing solid tumors: destiny-pantumor02 267 pts (t-dxd 5,4 mg/kg) orr
ihc 3+ 61.3%
ihc 2+ 27.2%
any grade ild 7.5% (1 pts g5) presented by. dr. funda meric-bernstam 
Medical Oncologist.                                            
        
On the trail of #SCIENCE to turn cancer into a manageable chronic disease. #bcsm #crcsm